title: One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother.
abstract: We describe the pharmacokinetics of raltegravir of a preterm newborn after short-course treatment of the mother tested HIV + the day of delivery. At age 1 month, the circulating concentration of raltegravir in the newborn was 29 ng/ml (the IC95 of RAL against HIV-1 is 15 ng/ml). Raltegravir should therefore be considered a potential transplacental postexposure prophylaxis for HIV-1 and an alternative to the use of boosted lopinavir in this context.
authors.affiliation: Infectious Diseases Unit, L.C. Fleming Hospital, Saint Martin, French West Indies.
authors.forename: C
authors.initials: C
authors.lastname: Clavel-Osorio
authors.forename: F
authors.initials: F
authors.lastname: Cazassus
authors.forename: S
authors.initials: S
authors.lastname: Stegmann
authors.forename: P
authors.initials: P
authors.lastname: Huc-Anaïs
authors.forename: D
authors.initials: D
authors.lastname: Lecam
authors.forename: G
authors.initials: G
authors.lastname: Peytavin
mesh_terms: D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D009035:Mothers; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000068898:Raltegravir Potassium
chemical_list: D011760:Pyrrolidinones; D000068898:Raltegravir Potassium